Journal of Drug Assessment · 2019 · 13 citations · 34 references
MedicineOncologyPharmacotherapyCancer PharmacologyEpidemiologic MethodsSurvival AnalysisCancer ImmunotherapyCancer StagingCancer Survival AnalysisMelanoma PharmacotherapyNetwork Meta-analysisTherapy Response AssessmentBayesian Network Meta-analysisMelanoma Adjuvant TherapyPd-l1 BlockadePembrolizumab TherapyPooled Hazard RatiosRandomized Clinical TrialsRecurrence-free SurvivalSystematic Literature Review
Objective: To determine the efficacy of pembrolizumab relative to other treatments used in stage III melanoma by conducting a systematic literature review (SLR) and network meta-analysis (NMA).Methods: A SLR was conducted to identify randomized clinical trials (RCTs) evaluating approved adjuvant treatments including interferon-containing regimens, BRAF-inhibitors, and PD-L1 inhibitors in stage III melanoma patients. Relative treatment effects for recurrence-free survival (RFS) were synthesized with Bayesian NMA models that allowed for hazard ratios (HRs) to vary over time.Results: Included studies formed a connected network of evidence composed of eight trials. In high-risk stage III patients, the HR for pembrolizumab vs observation decreased significantly over time with the superiority of pembrolizumab over observation becoming statistically meaningful before 3 months. By 9 months, the HR for pembrolizumab vs observation was statistically significantly lower than the HR for most other treatments vs observation, with the exception of ipilimumab and biochemotherapy due to overlapping 95% credible intervals. In BRAF + patients, pembrolizumab was statistically significantly better than observation after 3 months. The HR for both BRAF-inhibitors vs observation increased significantly over time and pembrolizumab was statistically superior to both BRAF-inhibitors after 15 months.Conclusions: Pembrolizumab results in statistically significantly improved RFS compared to all competing regimens after 9 months, except ipilimumab and biochemotherapy, for the adjuvant treatment of stage III melanoma. However, point estimate HRs vs observation for pembrolizumab are much lower than those for ipilimumab. In BRAF + patients, the advantage of pembrolizumab versus competing interventions increases over time with respect to RFS.
34
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins, Doug Altman, Peter C Gøtzsche et al. · BMJ · 2011 · 34.2K citations · Full text
SEER Cancer Statistics Review, 1975-2003
Lynn A. G. Ries, D. Harkins, Martin Krapcho et al. · ScholarWorks - Georgia State University (Georgia State University) · 2006 · 11.5K citations · Full text
Medicine, Biostatistics, Oncology +12
Christina Fitzmaurice, Christine A. Allen, Ryan M Barber et al. · JAMA Oncology · 2016 · 6.3K citations · Full text